| 000 | 01752 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250516043736.0 | ||
| 264 | 0 | _c20110909 | |
| 008 | 201109s 0 0 eng d | ||
| 022 | _a1715-3360 | ||
| 024 | 7 |
_a10.3129/i10-095 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAlmony, Arghavan | |
| 245 | 0 | 0 |
_aEfficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab. _h[electronic resource] |
| 260 |
_bCanadian journal of ophthalmology. Journal canadien d'ophtalmologie _cApr 2011 |
||
| 300 |
_a182-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 |
_aChoroidal Neovascularization _xdiagnosis |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFluorescein Angiography |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIntravitreal Injections |
| 650 | 0 | 4 |
_aMacular Degeneration _xdiagnosis |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aRanibizumab |
| 650 | 0 | 4 | _aRetreatment |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aTomography, Optical Coherence |
| 650 | 0 | 4 | _aTreatment Failure |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aVisual Acuity _xphysiology |
| 700 | 1 | _aMansouri, Azad | |
| 700 | 1 | _aShah, Gaurav K | |
| 700 | 1 | _aBlinder, Kevin J | |
| 773 | 0 |
_tCanadian journal of ophthalmology. Journal canadien d'ophtalmologie _gvol. 46 _gno. 2 _gp. 182-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3129/i10-095 _zAvailable from publisher's website |
| 999 |
_c20961661 _d20961661 |
||